Information Provided By: 
Fly News Breaks for October 9, 2018
EW
Oct 9, 2018 | 07:18 EDT
Canaccord analyst Jason Mills said the recent weakness in Edwards Lifesciences is a compelling buying opportunity. The analyst said it remains his top large-cap stock, which enjoys a favorable setup through the Partner 3 low-risk data in March 2019. He also noted the positive data release on the CENTERA U.S. pivotal trial as well as its positioning and strategy in the TAVR space. Mills reiterated his Buy rating and $177 price target on Edwards Lifesciences shares.
News For EW From the Last 2 Days
